Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Antiangiogenesis enhances intratumoral drug retention.

Ma J, Chen CS, Blute T, Waxman DJ.

Cancer Res. 2011 Apr 1;71(7):2675-85. doi: 10.1158/0008-5472.CAN-10-3242. Epub 2011 Mar 29.

2.

Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.

Ma J, Waxman DJ.

Clin Cancer Res. 2009 Jan 15;15(2):578-88. doi: 10.1158/1078-0432.CCR-08-1174.

3.

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.

Clin Cancer Res. 2008 Nov 15;14(22):7272-83. doi: 10.1158/1078-0432.CCR-08-0652.

5.

Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.

Chen CS, Jounaidi Y, Su T, Waxman DJ.

Cancer Gene Ther. 2007 Dec;14(12):935-44. Epub 2007 Sep 14.

6.

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.

Ma J, Waxman DJ.

Mol Cancer Ther. 2008 Jan;7(1):79-89. doi: 10.1158/1535-7163.MCT-07-0584.

7.

VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.

Doloff JC, Waxman DJ.

Cancer Res. 2012 Mar 1;72(5):1103-15. doi: 10.1158/0008-5472.CAN-11-3380. Epub 2012 Jan 11.

8.

Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.

Jounaidi Y, Hecht JE, Waxman DJ.

Cancer Res. 1998 Oct 1;58(19):4391-401.

9.

Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.

Zhang K, Waxman DJ.

Mol Cancer Ther. 2013 May;12(5):787-98. doi: 10.1158/1535-7163.MCT-12-1240. Epub 2013 May 1.

10.
11.
12.

Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps.

Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM.

Neuro Oncol. 2003 Oct;5(4):235-43.

15.

Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.

Lu L, Saha D, Martuza RL, Rabkin SD, Wakimoto H.

J Neurooncol. 2015 Jan;121(1):91-100. doi: 10.1007/s11060-014-1612-1. Epub 2014 Sep 12.

17.
18.

Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.

Manley E Jr, Waxman DJ.

J Pharmacol Exp Ther. 2013 Feb;344(2):368-77. doi: 10.1124/jpet.112.200089. Epub 2012 Nov 28.

20.

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.

Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V.

Cancer Biol Ther. 2008 Sep;7(9):1377-85. Epub 2008 Sep 2.

PMID:
18708754

Supplemental Content

Support Center